Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Odonate Therapeutics, Inc. ODT, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018, at 2:30 p.m. Eastern Time.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent belonging to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate recently initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer. Odonate's goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. To learn more, please visit www.odonate.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005468/en/